

4 June 2026

\$200 Million Debt Facility Executed to Accelerate Growth

Chrysos Corporation Ltd (ASX:C79) (“Chrysos” or the “Company”) is pleased to announce the successful refinancing of its corporate facilities with a new three-year AUD\$200m syndicated facility with three domestic financiers.

These new debt facilities move away from the Company's existing asset-based financing debt structure to a corporate-style facility designed to provide operational flexibility and support for, among other things, the development, production and funding of PhotonAssay™ units in numerous jurisdictions around the world.

Reflective of Chrysos' tier one customers and long-term committed revenue, the new debt facilities:

- Provide more favourable debt pricing relative to the existing facility
- Reduce the commitment fee on undrawn facilities relative to the existing facility
- Include improved covenants relative to the existing facility
- Increase funding headroom by \$105 million
- Will be drawn to extinguish the existing asset-based financing

Facility Details

The new corporate debt facilities will be provided by a syndicate of three financiers - Australia and New Zealand Banking Group Limited, National Australia Bank Limited and Export Finance Australia – and will consist of a term and a revolving facility, with an accordion mechanism for additional commitments or facilities to be added, subject to the agreed terms. Guarantees and security will be granted by the Company and a number of subsidiaries located in Australia and across certain foreign jurisdictions, including Canada, New Zealand, the United Kingdom and the United States of America with there being flexibility to add further jurisdictions.

The debt facilities contain a covenant package customary for corporate-style facilities of this nature, including representations and warranties, undertakings and events of default. A net leverage ratio and interest cover ratio has also been included. The facilities will be available for utilisation with customary drawdown conditions for facilities of this nature.

Funding in place to accelerate growth

The facility strengthens Chrysos' financial flexibility and provides capital to support manufacturing and deployments as global adoption of PhotonAssay™ continues to grow. The funding supports Chrysos' return to its target manufacturing cadence of 18 units per year, with the forward order book now extending to a further 22 PhotonAssay™ units and 27 long-lead components, positioning the Company for anticipated growth through FY27 and beyond.

Continued global adoption of PhotonAssay™

- Chrysos continues to experience strong commercial momentum, with a further four PhotonAssay™ lease agreements signed since the Company's last update, taking total new lease agreements signed year-to-date to 23, including an expanding global footprint with SGS and an additional unit for ALS - its second unit for Saudi Arabia.
- During May the Company achieved its third consecutive month of processing more than one million samples, with high utilisation across the PhotonAssay™ fleet supported by a buoyant gold market.
- Chrysos is currently deploying two units across two regions.



Chrysos Managing Director and CEO Dirk Treasure commented:

“We are pleased to have this facility in place to support the Company’s continued growth and accelerating deployment cadence. Continued adoption of PhotonAssay™ is driving strong demand across multiple regions, reflected in the additional four contracts signed with laboratories since our last update. The facility provides Chrysos with the flexibility and capital support required to scale deployments, expand our global footprint and maintain momentum as customer adoption continues to strengthen.”

ENDS

About Chrysos Corporation

Headquartered in Adelaide, with operations expanding across the world, Chrysos Corporation combines science and software to create technology solutions for the global mining industry. The Company’s flagship product PhotonAssay™ delivers faster, safer, more accurate and environmentally-friendly analysis of gold, silver, copper and other elements. For more information about Chrysos or its PhotonAssay™ technology, visit www.chrysoscorp.com

For media and investor enquiries, please contact:

Annalise Batchelor	Sodali & Co.	+61 432 312 807	annalise.batchelor@sodali.com
Paul Ryan	Sodali & Co.	+61 409 296 511	paul.ryan@sodali.com

This announcement was authorised for release by the Chair of Chrysos Corporation Limited.

For personal use only